Alnylam terminates revusiran program, stock plunges.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

30 citing papers in PubMed.

1. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data.ESC heart failure · 2021
   Trial
2. Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications.Molecular cancer · 2025
   Review
3. Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver.Journal of medicinal chemistry · 2025
   Review
4. The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems.Pharmaceutics · 2024
   Review
5. Advancements in clinical RNA therapeutics: Present developments and prospective outlooks.Cell reports. Medicine · 2024
   Review
6. RNAi-based drug design: considerations and future directions.Nature reviews. Drug discovery · 2024
   Review
7. Extracellular Vesicles: A New Star for Gene Drug Delivery.International journal of nanomedicine · 2024
   Review
8. Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin.Pharmacological reviews · 2023
   Review
9. Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies.Pharmaceutics · 2023
   Review
10. Recent insights into the functions and mechanisms of antisense RNA: emerging applications in cancer therapy and precision medicine.Frontiers in chemistry · 2023
    Review
11. RNA-based therapeutics: an overview and prospectus.Cell death & disease · 2022
    Review
12. Exosome-mediated delivery of RNA and DNA for gene therapy.Cancer letters · 2021
    Article
13. Transthyretin Stabilization: An Emerging Strategy for the Treatment of Alzheimer's Disease?International journal of molecular sciences · 2020
    Review
14. Advances in oligonucleotide drug delivery.Nature reviews. Drug discovery · 2020
    Review
15. Delivery of RNAi-Based Therapeutics for Bone Regeneration.Current osteoporosis reports · 2020
    Review
16. Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors.Drug design, development and therapy · 2020
    Review
17. Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone.Nature biomedical engineering · 2020
    Article
18. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.Advanced materials (Deerfield Beach, Fla.) · 2019
    Review
19. The current state and future directions of RNAi-based therapeutics.Nature reviews. Drug discovery · 2019
    Review
20. Clinical Cancer Nanomedicine.Nano today · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.